La lexicografía bilingüe italoespañola: traducción de algunos elementos culturales

1nonenoneMEDINA MONTERO J.F.MEDINA MONTERO, JOSE FRANCISC

Colorimetric Evaluation of Pictorial Coatings in Conservation of Plasterworks from the Islamic Tradition

The main aim of our current investigation is the colorimetric evaluation of protective treatments (consolidants) applied to traditional Islamic plasterworks, under natural ageing conditions. From analyses of the original pictorial plaster remains in the Courtyard of the Maidens of the Real Alcázar in Seville, Spain (a World Heritage Site) we prepared test specimens, using materials and techniques similar to the original ones. We analysed 56 test specimens painted with four pigments (yellow, green, blue, and red), using two different binders (animal glue and gum arabic), onto which five representative consolidants were applied: barium hydroxide, acrylic copolymer, polyvinyl butyral, ethyl silicate, and bacterial carbonatogenesis. The test specimens were subjected to natural ageing for one year (indoors and outdoors), enabling a colorimetric assessment to be made of the changes of the polychrome surfaces. The colorimetric heterogeneity of the 56 specimens after ageing registered an average value of 2.7 CIELAB units, assessed using the mean colour difference with respect to the mean. In the aged specimens, the addition of consolidants resulted in average colour differences (mainly lightness differences) of 10.7 and 6.7 CIELAB units, considering as a reference the specimens without consolidants aged indoors and outdoors, respectively. These colour differences were very similar for both binders but not for the four pigments, higher values being found for the blue and red pigments. Considering as reference the samples without consolidants aged outdoors, we found no statistically significant colour differences, either among the five consolidants (p = .094) nor the two binders (p = .674) used. In addition to the magnitude of colour differences, the choice of the most appropriate consolidants must also consider aspects related to performance and effectiveness. Overall, for the type of paints tested, the polyvinyl butyral consolidant appeared to perform the best, followed by the ethyl silicate.Ministerio de Economía y Competitividad (Gobierno de España), with support from European Regional Development Fund (ERDF), within the framework of Research Projects HAR2015-66139-P and FIS2016-80983-PConsejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (Research Project P12-HUM-1941)

Ensayos de tratamientos de protección y consolidación de la policromía del alfarje y yeserías del Patio de las Doncellas: Real Alcázar de Sevilla

El trabajo que se presenta pone de manifiesto la metodología llevada a cabo para la valoración de tratamientos, en lo que a color se refiere, aplicados sobre probetas de ensayo realizadas a partir de los materiales identificados en dos elementos arquitectónicos decorativos de la zona sur-este de uno de los patios más significativos del Alcázar de Sevilla: el Patio de las Doncellas. Estos elementos que tenemos como motivo de estudio son el alfarje de las galerías bajas y el paramento de yeso. Los tratamientos seleccionados para ser evaluados consisten, en el caso del alfarje en la aplicación de un barniz de protección con estabilizador de radiación ultravioleta (Archival Golden ®), y en el caso de las yeserías de aplicación de dos tratamientos de consolidación: resina acrílica (Paraloid®B72) y silicato de etilo (Bioestel®1200). Los resultados obtenidos servirán de base para la elección de una propuesta de intervención óptima que incluya la posible utilización del barniz ultravioleta en el alfarje in situ así como el efecto que podrían tener los tratamientos de consolidación en las policromías de las yeserías. De esta forma contribuimos al conocimiento previo del comportamiento de los materiales antes de abordar la restauración de la decoración arquitectónica de este espacio o de otras obras de similar cronología con problemáticas similares.The work presented shows the methodology conducted for evaluating treatments, in what concerns color, applied on test specimens made from the materials identified in two decorative architectural elements of the south-east one of the most important courts of the Alcazar of Seville: courtyard of the Maidens. These elements we have as a subject of study are the paneled ceiling of the lower galleries and the wall plaster. The treatments selected for evaluation consist in the case of alfarje in applying a protective varnish with ultraviolet radiation stabilizer, and in the case of plasterworks, applying two consolidation treatments: Paraloid ®B72 and Ethyl Silicate (Bioestel®1200). The results will form the basis for choosing an optimal intervention proposal that includes the possible use of UV varnish on the paneled ceiling and the effect that could have treatments consolidation of polychrome plasterwork. In this way, we contribute to the prior knowledge of the behavior of materials before boarding the restoration of the architectural decoration of this space or other works of similar chronology with similar problems.Esta investigación ha sido financiada por el Ministerio de Economía y Competitividad y por el Fondo Europeo de Desarrollo Regional (FEDER) en el marco del Proyecto de Investigación “Estudio científico y tratamientos de conservación de revestimientos arquitectónicos de época romana a medieval” de referencia (HAR2015-66139-P) así como el proyecto del Ministerio de Innovación y Ciencia denominado “Decoración arquitectónica de tradición islámica. Materiales y técnicas de ejecución” (HAR 2011-27598). Igualmente ha sido posible gracias a la beca contrato puente de la Universidad de Granada de la que es beneficiaria Ana Isabel Calero Castillo

Restauración del Patrimonio de la Universidad de Granada (I)

La serie editorial de Cuadernos Técnicos del Patrimonio surge debido a la necesidad de dotar al Vicerrectorado de Extensión Universitaria de publicaciones que aborden aspectos patrimoniales en relación con cuestiones de carácter transversal y que sirvan de vehículo de difusión y diálogo de las distintas colecciones que conforman el rico acervo universitario. El objetivo es convertir estos Cuadernos en un espacio de reflexión y debate sobre temas relacionados con la conservación, la restauración, la gestión, la difusión y la puesta en valor de los bienes muebles e inmuebles de la Universidad de Granada en toda su amplitud. No se plantean con un enfoque exclusivamente local pues su intención es abrirse a distintas problemáticas patrimoniales y convertirse en un instrumento que integre estudios de carácter nacional e internacional. Asimismo, entendemos que al Patrimonio hay que afrontarlo desde una perspectiva histórica pero también actual y en diálogo con la compleja realidad social

CIBERER : Spanish national network for research on rare diseases: A highly productive collaborative initiative

Altres ajuts: Instituto de Salud Carlos III (ISCIII); Ministerio de Ciencia e Innovación.CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low-prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15-year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research

Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study

Limited data are available on the effectiveness and tolerability of direct-acting antivirals (DAAs) therapies in the real world for HCV-infected patients with comorbidities. This study aimed to describe the effectiveness of OBV/PTV/r ± DSV (3D/2D regimen) with or without ribavirin (RBV) in HCV or HCV/HIV co-infected patients with GT1/GT4 and CKD (IIIb-V stages), including those under hemodialysis and peritoneal dialysis in routine clinical practice in Spain in 2015.Non-interventional, retrospective, multicenter data collection study in 31 Spanish sites. Socio-demographic, clinical variables, study treatment characteristics, effectiveness and tolerability data were collected from medical records.Data from 135 patients with a mean age (SD) of 58.3 (11.4) years were analyzed: 92.6% GT1 (81.6% GT1b and 17.6% GT1a) and 7.4% GT4, 14 (10.4%) HIV/HCV co-infected, 19.0% with fibrosis F3 and 28.1% F4 by FibroScan®, 52.6% were previously treated with pegIFN and RBV. 11.1%, 14.8% and 74.1% of patients had CKD stage IIIb, IV and V respectively. 68.9% of patients were on hemodialysis; 8.9% on peritoneal dialysis and 38.5% had history of renal transplant. A total of 125 (96.2%) of 135 patients were treated with 3D, 10 (7.4%) with 2D and 30.4% received RBV. The overall intention-to-treat (ITT) sustained virologic response at week 12 (SVR12) was 92.6% (125/135) and the overall modified-ITT (mITT) SVR12 was 99.2% (125/126). The SVR12 rates (ITT) per sub-groups were: HCV mono-infected (91.7%), HCV/HIV co-infected (100%), GT1 (92.0%), GT4 (100%), CKD stage IIIb (86.7%), stage IV (95%) and stage V (93%). Among the 10 non-SVR there was only 1 virologic failure (0.7%); 4 patients had missing data due lost to follow up (3.0%) and 5 patients discontinued 3D/2D regimen (3.7%): 4 due to severe adverse events (including 3 deaths) and 1 patient´s decision.These results have shown that 3D/2D regimens are effective and tolerable in patients with advanced CKD including those in dialysis with GT 1 or 4 chronic HCV mono-infection and HIV/HCV coinfection in a real-life cohort. The overall SVR12 rates were 92.6% (ITT) and 99.2% (mITT) without clinically relevant changes in eGFR until 12 weeks post-treatment. These results are consistent with those reported in clinical trials

Estimating the global conservation status of more than 15,000 Amazonian tree species

Estimates of extinction risk for Amazonian plant and animal species are rare and not often incorporated into land-use policy and conservation planning. We overlay spatial distribution models with historical and projected deforestation to show that at least 36% and up to 57% of all Amazonian tree species are likely to qualify as globally threatened under International Union for Conservation of Nature (IUCN) Red List criteria. If confirmed, these results would increase the number of threatened plant species on Earth by 22%. We show that the trends observed in Amazonia apply to trees throughout the tropics, and we predict thatmost of the world’s >40,000 tropical tree species now qualify as globally threatened. A gap analysis suggests that existing Amazonian protected areas and indigenous territories will protect viable populations of most threatened species if these areas suffer no further degradation, highlighting the key roles that protected areas, indigenous peoples, and improved governance can play in preventing large-scale extinctions in the tropics in this century

Hyperoxemia and excess oxygen use in early acute respiratory distress syndrome : Insights from the LUNG SAFE study

Publisher Copyright: © 2020 The Author(s). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.Background: Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with acute respiratory distress syndrome (ARDS). We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study. Methods: In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients with early ARDS. Patients who fulfilled criteria of ARDS on day 1 and day 2 of acute hypoxemic respiratory failure were categorized based on the presence of hyperoxemia (PaO2 > 100 mmHg) on day 1, sustained (i.e., present on day 1 and day 2) hyperoxemia, or excessive oxygen use (FIO2 ≥ 0.60 during hyperoxemia). Results: Of 2005 patients that met the inclusion criteria, 131 (6.5%) were hypoxemic (PaO2 < 55 mmHg), 607 (30%) had hyperoxemia on day 1, and 250 (12%) had sustained hyperoxemia. Excess FIO2 use occurred in 400 (66%) out of 607 patients with hyperoxemia. Excess FIO2 use decreased from day 1 to day 2 of ARDS, with most hyperoxemic patients on day 2 receiving relatively low FIO2. Multivariate analyses found no independent relationship between day 1 hyperoxemia, sustained hyperoxemia, or excess FIO2 use and adverse clinical outcomes. Mortality was 42% in patients with excess FIO2 use, compared to 39% in a propensity-matched sample of normoxemic (PaO2 55-100 mmHg) patients (P = 0.47). Conclusions: Hyperoxemia and excess oxygen use are both prevalent in early ARDS but are most often non-sustained. No relationship was found between hyperoxemia or excessive oxygen use and patient outcome in this cohort. Trial registration: LUNG-SAFE is registered with ClinicalTrials.gov, NCT02010073publishersversionPeer reviewe

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049